


RO5166017

| | |
|---------------------------|--|
| Cat. No.: | HY-12699 |
| CAS No.: | 1048346-74-2 |
| Molecular Formula: | C ₁₂ H ₁₇ N ₃ O |
| Molecular Weight: | 219.28 |
| Target: | Trace Amine-associated Receptor (TAAR) |
| Pathway: | GPCR/G Protein |
| Storage: | -20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |



SOLVENT & SOLUBILITY

| | | | | | | |
|---|---|----------------------|-------------|-------------|-------------|--------------|
| In Vitro | DMSO : 25 mg/mL (114.01 mM; Need ultrasonic) | | | | | |
| | Preparing Stock Solutions | Solvent | Mass | 1 mg | 5 mg | 10 mg |
| | | Concentration | | | | |
| | | 1 mM | | 4.5604 mL | 22.8019 mL | 45.6038 mL |
| | | 5 mM | | 0.9121 mL | 4.5604 mL | 9.1208 mL |
| | 10 mM | | 0.4560 mL | 2.2802 mL | 4.5604 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution | | | | | |
| | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (11.40 mM); Suspended solution; Need ultrasonic | | | | | |
| | 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution | | | | | |

BIOLOGICAL ACTIVITY

| | |
|--------------------|--|
| Description | RO5166017 is an orally active and species-crosses TAAR1 agonist, with K _i values of 1.9 nM, 2.7 nM, 31 nM and 24 nM for mouse, rat, human and cynomolgus monkey, respectively ^[1] . |
| In Vitro | RO5166017 showed high affinity and potent functional activity at mouse, rat, cynomolgus monkey, and human TAAR1 stably expressed in HEK293 cells as well as high selectivity vs. other targets ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| In Vivo | RO5166017 prevents stress-induced hyperthermia and blocked dopamine-dependent hyperlocomotion in cocaine-treated and dopamine transporter knockout mice as well as hyperactivity induced by an NMDA antagonist ^[1] . |

?RO5166017 (0.01-1 mg/kg, orally) dose-dependently prevents the SIH in NMRI mice. RO5166017 exhibits TAAR1-mediated anxiolytic-like properties at doses 0.1-0.3 mg/kg.^[1]

?RO5166017 prevents the cocaine-induced hyperlocomotion. RO5166017 also inhibits stereotypies induced by cocaine in WT mice similar to olanzapine, and this effect is lost in Taar1^{2/2} mice^[1].

?TAAR1 activation by RO5166017 increases glucose-dependent insulin secretion in INS1E cells and human islets and elevated plasma and peptide YY (PYY) and glucagon like peptide 1 (GLP-1) levels in mice^[2].?Subchronic treatment of diet-induced obese (DIO) mice with RO5166017 results in reduced food intake and body weight^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Oregon Health and Science University. 2023 Jun 29.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Florent G Revel, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A

[2]. Justin N Siemian, et al. Trace amine-associated receptor 1 agonists RO5263397 and RO5166017 attenuate quinpirole-induced yawning but not hypothermia in rats. Behav Pharmacol. 2017 Oct;28(7):590-593.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA